The Implications of the Shift Toward Donation After Circulatory Death in Australia

Janske Reiling, MD, PhD,1,2,3,4 Elizabeth Forrest, MBBS,5 Kim R. Bridle, PhD,1,3 Laurence J. Britton, MBChB, FRACP,1,3 Nishreen Santrampurwala, PhD,1,3 Darrell H.G. Crawford, MBBS, MD, FRACP,1,3 Cornelis H.C. Dejong, MD, PhD, FRCSEd (Hon),4,6 Jonathan Fawcett, DPhil, FRACS, FRCS1,6,7

Background. In recent years, an increasing number of donor livers are being declined for transplantation in Australia. The aim of this study was to evaluate the impact of donation after cardiac death and other factors associated with organ quality on liver utilization rates in Australia. Methods. Data on organ donors who donated at least 1 organ between 2005 and 2014 were obtained from the Australia and New Zealand organ donation registry. Temporal changes in donor characteristics were assessed and a logistical regression analysis was performed to evaluate their association with liver nonuse. Results. The number of organ donors increased from 175 in 2005 to 344 in 2014, with overall 19% being donation after cardiac death donors (P < 0.001). The percentage of livers deemed unsuitable for transplantation increased from 24% in 2005 to 41% in 2014 (P < 0.001). Donation after cardiac death was identified as the most important risk factor for nonuse with an odds ratio of 25.88 (95% confidence interval, 18.84-35.56), P < 0.001) followed by donor age, obesity, and diabetes. Discussion. This study shows that livers donated after circulatory death are an underused resource in Australia. Better use of these currently available organs would be a highly cost-effective way of reducing waiting list mortality in liver transplantation.

(Accepted 8 September 2017. Received 23 January 2017. Revision requested 6 September 2017.)

A shortage of available donors remains a major limiting factor in the field of liver transplantation. Currently in Australia, only 50% of patients with end-stage liver disease on the waiting list receive a life-saving transplant each year. At the same time, 10% of patients die or their condition deteriorates to the point that they are no longer deemed suitable for transplant.1 In 2008, the Australian Federal Government announced a reform program to increase the number of organ donors. As a result, organ donor rates increased from 12 to 16.1 per million population.2 Unfortunately, the number of livers available for transplantation has failed to increase at the same rate, suggesting that more livers are deemed unsuitable for transplantation.1,2

As well as encouraging the use of extended criteria livers (eg, older donors and steatotic livers) and a drive to maximize splitting of suitable donor livers, one of the main strategies adopted has been the promotion of controlled donation after circulatory death (DCD; Maastricht classification type III). Currently, 28% of organ donors in Australia are DCD donors, which is low compared to the United Kingdom and the Netherlands, where 40% to 45% of organ donors are DCD donors.2,4,5 Donation after circulatory death lung and kidney programs have been very successful with graft and patient analysis, and reviewed and edited the manuscript. K.B., L.B., and N.S. helped design the study, and reviewed and edited the manuscript. D.C., C.D., and J.F. designed the study, supervised data collection and analysis, and edited and approved the final manuscript.

Correspondence: Janske Reiling, MD, PhD, Faculty of Medicine, the University of Queensland, Lower Lobby Level, Admin Building, Greenslopes Private Hospital, Greenslopes, Queensland 4120. (j.reiling@uq.edu.au).

Copyright © 2017 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000743
survival rates comparable to conventional donation after brain death (DBD) organs. Unfortunately, the experience has not been the same for liver transplantation. Donation after circulatory death livers are more susceptible to ischemia-reperfusion injury and their use has been associated with the development of nonanastomotic biliary strictures in 9% to 31% of recipients. As a result, the percentage of liver nonuse attributable to DCD has increased in the United States from 9% in 2004 to 28% in 2010. It is currently unclear what effect DCD donation has on liver nonuse in Australia.

The aim of this study was to evaluate the impact of DCD and other donor characteristics associated with more marginal donors on liver nonuse in Australia over the past 10 years. The study also aimed to further characterize the DCD donors, declined for transplantation, and to identify whether better selection criteria could potentially improve use in the future.

MATERIALS AND METHODS

Study Population

All adult organ donors in Australia who donated at least 1 organ between January 1, 2005 and January 1, 2015 were included in this study. As these donors had no absolute contraindication for the organ donation process, unsuitability for transplantation was most likely the result of liver-specific reasons. A liver donor was defined as an organ donor from whom the liver was retrieved and subsequently transplanted into a recipient. Deidentified donor data were obtained from the Australia and New Zealand Organ Donor (ANZOD) registry. In 1 Australian jurisdiction, the state of Queensland, approval was obtained from the human research ethics committee of the Princess Alexandra Hospital as well as the University of Queensland to access confidential donor data. This allowed access to donor files when data were incomplete or not available from the organ donor registry.

Data Collection

Donor demographics associated with marginal grafts such as donor age, body mass index (BMI), donation type (DCD or DBD), hepatitis B (hepatitis B surface antigen positive) or hepatitis C infection (hepatitis C virus antibody positive and presence of hepatitis C virus RNA by nucleic acid testing), hypertension, and diabetes mellitus were collected. As donor age was not normally distributed, the following age categories were used: younger than 40, 40 to 49, 50 to 59, and older than 60 years. Body mass index was classified as underweight (<18.5 kg/m²), normal weight (18.5–24.99 kg/m²), overweight (25–29.99 kg/m²), and obese (>30 kg/m²). Liver biopsy results were not included from any of the donors, as it is not routine practice to perform a biopsy and the inclusion of biopsy results of selected donors would bias the results. Owing to incomplete data in the organ donor registry during this period, it was not possible to include liver function test results as a parameter in the main analyses. Instead, a subanalysis was performed of the Queensland state donors (n = 468), where alanine aminotransferase (ALT) was categorized as less than 100 versus greater than 100 U/L, bilirubin as less than 20 versus greater than 20 μmol/L, and γ-glutamyl transferase as less than 40 versus greater than 40 U/L.

Additional factors that potentially influence the decision to use a liver for donation such as sex, blood group, presence of hepatitis B core antibody, year of organ retrieval, state of

RESULTS

Donor Characteristics

Between 2005 and 2014, a total of 2547 organ donors in Australia were identified who donated at least a single organ (Table 1). Of these, most organ donors were Caucasian (93%) and 55% were men. In addition, 706 (28%) were older than 60 years, 470 (19%) were DCD, and 957 (38%) and 623 (25%) were overweight or obese, respectively. Only a very small proportion of organ donors tested positive for hepatitis B or hepatitis C (0.3% and 1%, respectively), 8% were diabetic, and 27% had a history of hypertension. Stroke was the most common cause of death (54%) followed by hypoxia. The median number of organs transplanted per donor was 3. Most of the organ donors donated 1 or both kidneys (94%) followed by liver (65%), lung (43%), pancreas (32%), and heart (28%).
Changes in Donor Characteristics Over Time

Over the 10-year study period, the number of organ donors per year almost doubled from 175 in 2005 to 344 in 2014 (Figure 1). Since 2008, there has been a steady increase in the number of DCD organ donors, with 28% of all organs donated being from a DCD donor in 2014. In 2005, the percentage of organ donors younger than 40 years was 30%, which decreased to 24% in 2014. In contrast, the proportion of organ donors older than 60 increased by 10%. During the study period, the proportion of overweight and obese donors remained stable with a median BMI of 26 kg/m² (24-30 kg/m²). More donors were current or former smokers or died from hypoxic injury in 2014, compared with 2005 (Table 1). Overall, the median number of organs retrieved and transplanted per donor decreased from 4 (3-5) in 2005 to 3 (2-4) in 2014 ($P < 0.001$).

Temporal Trends in Liver Nonuse

Overall, a liver was retrieved and subsequently transplanted from 1643 organ donors (65%). Over time, the proportion of livers deemed unsuitable for transplantation from DBD donors remained stable between 20% and 30% (Figure 2). Since 2005, only 64 DCD livers (14%) were used for transplantation. Over the 10-year study period, the percentage of DCD livers rejected for transplantation was between 80% and 100% on an annual basis. As the proportion of DCD donors has increased over time, the overall number of livers not used for transplantation increased from 42 (24%) in 2005 to 141 (41%) in 2014 ($P < 0.001$).

Risk Factors for Liver Nonuse

In univariable analysis, liver nonuse was strongly associated with DCD donor type ($P < 0.001$; Table 2). Furthermore, livers from older donors and overweight or obese donors were less likely to be used. Organs from donors who died from hypoxia, compared to those who suffered a stroke, were more likely to be declined for transplant. In addition, liver nonuse was associated with donors who were former smokers, compared to those who did not smoke. The presence of hypertension and diabetes in the donor population was also associated with liver nonuse. In the subgroup of 468 DCD donors, a WIT of more than 20 minutes was associated with liver nonuse (odds ratio [OR], 3.05 [95% confidence interval [CI], 1.70-5.49], $P < 0.001$). In univariable analysis of Queensland state organ donors, ALT concentration of greater than 100 U/L and γ-glutamyl transferase greater than 40 U/L were associated with liver nonuse (OR, 3.01 [95% CI, 1.81-4.99], $P < 0.001$ and OR, 13.30 [95% CI, 7.99-22.12], $P < 0.001$, respectively).

### Table 1

| Donor characteristics between 2005 and 2014 |
|-------------------------------------------|
| Characteristic                            | 2005 (N = 175) | 2014 (N = 344) | Overall (N = 2547) | $P$  |
| Age, yrs                                  | 47 (36-56)     | 51 (40-60)     | 50 (37-60)         | 0.008 |
| Sex, male                                 | 91 (52%)       | 188 (55%)      | 1401 (55%)         | 0.5   |
| Race, Caucasian                           | 164 (94%)      | 307 (89%)      | 2359 (93%)         | 0.1   |
| Body mass index, kg/m²                     | 26 (24-29)     | 27 (24-30)     | 26 (24-30)         | 0.5   |
| Donor type (DBD)                          | 167 (95%)      | 249 (72%)      | 2077 (82%)         | $<0.001$ |
| Cause of death                            | Stroke         | 106 (61%)      | 174 (51%)          | $<0.001$ |
|                                            | Hypoxia        | 17 (10%)       | 99 (29%)           | 0.1   |
|                                            | Accident       | 28 (16%)       | 48 (14%)           | 0.2   |
|                                            | Other          | 24 (14%)       | 21 (7%)            | 0.7   |
|                                            | Diabetes mellitus | 13 (7%)   | 22 (8%)            | 0.5   |
|                                            | Hypertension   | 44 (25%)       | 96 (28%)           | 0.01  |
|                                            | Current        | 62 (35%)       | 152 (44%)          | 9030 (40%) |
|                                            | Never          | 81 (46%)       | 109 (32%)          | 910 (36%) |
|                                            | Former         | 32 (18%)       | 83 (24%)           | 601 (24%) |
| Hepatitis B core antibody                  | 11 (6%)        | 18 (5%)        | 130 (6%)           | 0.02  |
| Hepatitis B surface antigen                | 0 (0%)         | 5 (2%)         | 7 (0.3%)           | 0.2   |
| Hepatitis C antibody + HCV RNA             | 3 (2%)         | 2 (1%)         | 21 (1%)            | 0.2   |
| WIT, min                                   | Data not available | 23 (20-28)     | 22 (18-27)         | –     |
| ALT, U/L                                   | 28 (16-85)     | 42 (23-68)     | 38 (22-69)         | 0.5   |
| Bilirubin, μmol/L                          | 13 (7-16)      | 13 (9-18)      | 12 (8-17)          | 0.4   |
| Gamma-GT, (UL)                            | 41 (22-75)     | 32 (19-59)     | 42 (23-70)         | 0.4   |
| Distance donor hospital, km                | 8 (0-492)      | 67 (8-798)     | 40 (6-291)         | 0.2   |
| Number of organs retrieved and transplanted | 4 (3-5)         | 3 (2-4)        | 3 (3-5)            | $<0.001$ |

*a* Available from 387 (82%) of DCD donors.

*b* The data presented here are from the Queensland state donor subgroup only, N = 468.

Because of rounding, not all percentages add up to 100%.

$P$ values indicates statistically significant.

HCV, hepatitis C virus.
with an OR of 25.88 (95% CI, 18.84-35.56) (P < 0.001; Table 2). Furthermore, donor age older than 40 years was associated with liver nonuse with livers from donors older than 60 years being the least likely to be used (OR, 3.66 [95% CI, 2.62-5.11], P < 0.001). Donor obesity was also associated with higher odds for nonuse (P < 0.001) as was diabetes. In the Queensland state organ donor subset, ALT greater than 100 U/L and \( \gamma \)-glutamyl transferase greater than 40 U/L were strongly associated with nonuse (OR, 4.99 [95% CI, 2.23-11.19], P < 0.001 and OR, 12.21 [95% CI, 6.20-24.02], P < 0.001, respectively).

**Characteristics of DCD Nonliver Donors in the State of Queensland**

Since 2008, there were 91 DCD organ donors in the state of Queensland, but only 10 livers retrieved from these donors were used for transplantation. Compared to DBD donors, DCD donors were more often in the metropolitan area (88% vs 65%, P < 0.001). Most of the DCD nonliver donors (85%) had a WIT of less than 30 minutes and 27 (33%) had recorded a WIT less than 20 minutes. Furthermore, 36 nonliver donors (44%) were younger than 50 years, and 16 (44%) of those had a normal BMI.

Donor chart analysis showed that before mid-2011, no active DCD liver transplant program was in place. From 2011 onward, the main reason DCD livers were not used for transplantation was donor age (33 [41%]; Figure 3). Other reasons were medical suitability (6 [7%], eg, ischemic damage to the liver), logistics (4 [5%], eg, 2 concurrent donors) and no suitable recipient (2 [2%], eg, no recipient with the correct blood group).

**DISCUSSION**

In recent years, DCD donors have been identified as a potential source to increase donor numbers. The use of lungs and kidneys donated after circulatory death have been widely adopted in Australia.\textsuperscript{13,14} More recently, the first successful transplant of a normothermically perfused DCD heart was performed by our colleagues at St Vincent’s Hospital in Sydney.\textsuperscript{15} Unfortunately, the experience with DCD donor livers is rather different. Although the number of organ donors and the number of liver donors substantially increased over the study period, a greater proportion of livers were

![FIGURE 1. Changing organ donor characteristics between 2005 and 2014. A, Increase in the number of organ donors and organ donors donating their liver (liver donors) between 2005 and 2014. B, Number of livers donated after circulatory death (DCD) and donated after brain death (DBD) between 2005 and 2014. C, Age of organ donors between 2005 and 2014. D, Body mass index (BMI, kg/m\(^2\)) of organ donors between 2005 and 2014.](image-url)

![FIGURE 2. Increased percentage of liver nonuse between 2005 and 2014. This graph shows DCD (gray bars) and DBD (black bars) nonliver donors as a percentage of all organ donors from the corresponding donor type. The black line represents the overall percentage of livers not used for transplantation when the 2 donor types were combined.](image-url)
deemed unsuitable for transplantation. This was associated with an increase in DCD livers, which were not accepted for transplantation.

The decreasing rate of liver use is a pressing problem around the globe. In the United Kingdom, the proportion of livers used for transplantation has dropped from 79% (n = 601) in 2005-2006 to 63% (n = 812) in 2014-2015. Further, Osman et al found that in the United States, liver nonuse increased from 15% in 2004 to 21% in 2010, with DCD as the most important risk factor (OR, 21.31 [95% CI, 18.30-24.81]). The present study indicates that liver nonuse is an even bigger problem in Australia, as the proportion of DCD donors in the total cohort is higher. Australian centers have had a conservative approach to the use of DCD livers because a small population (24 million) limits access to emergency retransplantation in the event of primary nonfunction. Therefore, livers from DCD donors are rarely considered for transplantation if they are older than 40 to 45 years, in an attempt to select more superior grafts. This despite favorable outcomes of the use of older DCD donors reported in the United Kingdom and the Netherlands.

One of the most important questions currently is whether some DCD donors, if given the time, would in fact progress to brain death. If so, this would mean that a proportion of DBD organ donors, with expected good organ quality, were converted into the less favorable DCD type, which the present study shows is associated with high odds of liver nonuse. Reasons for this conversion could be that the DCD donation process is easier to comprehend by donor families and they prefer to accompany their family member until cardiac arrest has occurred. Furthermore, bed capacity in the intensive care unit could put pressure on the time-consuming neurological observations required to medically and legally determine brain death. A recent study assessing transplant rates in 82 countries showed that between 2000 and 2010, countries with high DCD rates had declining or static DBD rates. Furthermore, this study by Bendorf et al showed that the increase in the number of DBD donors, and not DCD, was the basis of higher sustained donation rates of more than 20 per million population in countries such as Spain, France, and the United States. Taken together, this might indicate that the focus needs to shift back to increasing the number of DBD donors.

To facilitate the use of high-risk donors such as DCD, risk factors such as WIT, cold ischemic time, and distance traveled need to be modified. Currently in Australia, withdrawal of life support takes place in the intensive care unit. After cessation

### TABLE 2

| Characteristic | Univariable regression | Multivariable regression<sup>a</sup> |
|---------------|------------------------|-------------------------------------|
|               | Odds ratio (95% CI)     | P                                   | Odds ratio (95% CI)     | P                                   |
| Age (vs < 40), yrs |                        |                                     |                        |                                     |
| 40-50         | 1.64 (1.28-2.11)        | <0.001                              | 1.67 (1.21-2.33)        | 0.002                               |
| 50-60         | 2.26 (1.79-2.87)        | <0.001                              | 2.34 (1.70-3.22)        | <0.001                              |
| > 60          | 2.75 (2.19-3.66)        | <0.001                              | 3.66 (2.62-5.11)        | <0.001                              |
| BMI (vs 18.5-24.99), kg/m<sup>2</sup> |                        |                                     |                        |                                     |
| < 18.5        | 1.46 (0.79-2.68)        | 0.2                                 | 1.81 (0.87-3.77)        | 0.1                                 |
| 25-29.99      | 1.33 (1.09-1.62)        | 0.005                               | 1.28 (0.99-1.64)        | 0.06                                |
| > 30          | 2.58 (2.23-3.41)        | <0.001                              | 3.02 (2.31-3.95)        | <0.001                              |
| Cause of death (vs stroke) |                    |                                     |                        |                                     |
| Hypoxia       | 1.75 (1.43-2.15)        | <0.001                              | 1.33 (1.00-1.76)        | 0.05                                |
| Accident      | 0.95 (0.74-1.20)        | 0.6                                 | 0.99 (0.71-1.37)        | 0.9                                 |
| Other         | 0.75 (0.72-1.27)        | 0.7                                 | 1.08 (0.74-1.58)        | 0.7                                 |
| Hypertension  | 1.63 (1.36-1.95)        | <0.001                              | 1.19 (0.93-1.52)        | 0.2                                 |
| Diabetes mellitus | 1.74 (1.31-2.32)    | <0.001                              | 1.61 (1.13-2.27)        | 0.008                               |
| Smoking (vs never) |                  |                                     |                        |                                     |
| Current       | 0.73 (0.60-0.88)        | 0.001                               | 0.83 (0.65-1.05)        | 0.1                                 |
| Former        | 1.16 (0.94-1.43)        | 0.2                                 | 0.97 (0.74-1.25)        | 0.8                                 |
| Hepatitis B core antibody | 1.11 (0.77-1.60)  | 0.6                                 | 2.59 (0.43-15.56)       | 0.3                                 |
| Hepatitis B surface antigen | 4.57 (0.88-23.58) | 0.07                               |                        |                                     |
| Hepatitis C antibody + HCV RNA | 0.57 (0.21-1.55) | 0.3                                 |                        |                                     |

<sup>a</sup> All factors with P < 0.1 in univariable regression analysis as well as ABO blood group, donor state, year (continuous), race, and sex were included in the multivariable regression model.

<sup>P</sup> values indicates statistically significant.

---

FIGURE 3. Reasons for DCD liver nonuse in Queensland between 2005 and 2014. This graph provides the reasons why DCD livers were not used for transplantation. After the introduction of a DCD liver transplant program in 2011, DCD livers were not used because of donor age (n = 33), medical suitability (n = 6), logistics (n = 4), no suitable recipient (n = 2), other (n = 1), and not given (n = 1).
of circulation, a legally obligated 5-minute stand down period is in place to make sure that autoresuscitation does not occur. The organ donor is then brought into the operating room, which can take 3 to 4 minutes. Withdrawal of life support in the operating room would significantly reduce travel time, especially during peak hour. Unfortunately, this is not possible in most states. By far the most effective way to reduce travel time is to focus on metropolitan donors only. This approach has facilitated the use of extended criteria livers (DCD, 10; DBD, 2) they perfused would be on the overall number of livers available for transplantation. Nevertheless, the biggest challenge to date is to build the confidence among transplant surgeons and physicians that the use of DCD donor livers can be safe. Despite the favorable graft and patient survival of DCD liver transplant programs in the United Kingdom and The Netherlands, even those DCD grafts that fulfill the current acceptance criteria in our cohort were not used for transplantation. Unfortunately, we were unable to determine the exact reasons for this.

The use of alternative preservation methods such as machine perfusion could be the solution to facilitate the use of DCD donor livers for transplantation. Machine perfusion reduces the preservation injury and therefore holds the potential to better preserve organ quality and possibly even rescue marginal donors who are outside current criteria (eg, DCD donor organs with WIT >30 minutes and macrovesicular steatosis >30%). Machine perfusion further opens up the possibility for organ sharing and use of marginal donors between geographically distant centers in Australia as preservation periods could be extended. Lastly, normothermic machine perfusion allows for assessment of viability, an important tool to avoid transplanting a liver that would in fact fail to function. The ability to directly assess liver function may offer a rational alternative to the use of current empirical criteria for selection of DCD livers for transplantation. As the application of machine perfusion is still an upcoming new technique, it is difficult to predict what the impact would be on the overall number of livers available for transplantation. Sutton et al estimated that 50% of the discarded extended criteria livers (DCD, 10; DBD, 2) they perfused showed signs of good organ function. Furthermore, based on results of a pilot series, Mergental et al estimated a potential 15% if 70% of currently declined extended criteria livers could be used.

The limitations of the study arise mainly from its retrospective nature. The reasons for nonuse of each organ are registered in the nationwide database, but in most cases, this was not well defined (eg, ‘medical unsuitability’ or DCD). Furthermore, no histological data were available to determine the impact of hepatic steatosis. Obesity and diabetes mellitus were however included in the cohort, and these factors are strongly associated with hepatic steatosis. Finally, it was only possible to assess the impact of abnormal liver function tests and donor hospital location in the Queensland state donor cohort. As this cohort only comprised 18% of all Australian organ donors, it might not represent the entire study cohort.

Despite these limitations, this study shows that livers donated after circulatory death are an underused resource in Australia. Better use of these currently available organs would be a highly cost-effective way of reducing waiting list mortality in liver transplantation.

ACKNOWLEDGMENTS

The authors acknowledge the ANZOD Registry for kindly providing organ donor information. With regard to the provided data, ANZOD has stated the following: The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the Australia and New Zealand Organ Donation. The authors likewise thank Jade Carey from DonateLife Queensland for her help with data collection and the Gallipoli Medical Research Foundation for their support and facilities.

REFERENCES

1. ANZLTR. ANZLTR 24th Annual Report, Australia and New Zealand Liver Transplant Registry. 2014.
2. Australian Organ and Tissue Donation Authority. Annual Report, 2014-2015. 2015.
3. Kootstra G, Daemen JH, Oomen AP. Categories of non–heart-beating donors. Transplant Proc. 1995;27:2893–2894.
4. Nederlandse Transplantatie Stichting. Jaarverslag, 2014.
5. NHS. Blood and transplant. Organ Donation and Transplantation Activity Report 2014/15. 2015.
6. Machuca TN, Mercier O, Collaud S, et al. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion. Am J Transplant. 2015;15:993–1002.
7. Summers DM, Watson CJ, Pettigrew GJ, et al. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88:241–249.
8. Dubeibeld J, Hoekstra H, Farid W, et al. Similar liver transplantation survival with selected cardiac death donors and brain death donors. Br J Surg. 2010;97:744–753.
9. Laing RW, Scalena I, Isaac J, et al. Liver transplantation using grafts from donors after circulatory death: a propensity score–matched study from a single center. Am J Transplant. 2016;16:1795–1804.
10. Orman ES, Barrett AS, Wheeler SB, et al. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl. 2013;19:59–68.
11. National Health and Medical Research Council, Australian Organ and Tissue Donation and Transplantation Authority. National Protocol for Donation After Circulatory Death. 2010.
12. van der Stelt JM, Verrall DJ, deRoo RA, et al. Initial outcomes of using allotrafts from donation after cardiac death donors for liver transplantation in New South Wales. Med J Aust. 2013;199:104–106.
13. Snell GI, Levey BJ, Westall GP. The changing landscape of lung donation for transplantation. Am J Transplant. 2015;15:859–860.
14. Kumar RA, Shekar K, Widdicombe N, et al. Donation after cardiac death in Queensland: review of the pilot project. Anaesth Intensive Care. 2012;40: 517–522.
15. Macdonald P. Heart transplantation from donation after circulatory death: the impact of global warming. Am J Transplant. 2016;16:737–738.
16. Transplant activity in the UK 2005–2006. Bristol, UK: NHS Blood and Transplant; 2006.
17. Blick JJ, Detty O, Putter H, et al. Long-term results of liver transplantation from donation after circulatory death. Liver Transpl. 2016;22:1107–1114.
18. Detty O, Deroover A, Meurisse N, et al. Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol programme. Br J Surg. 2014;101:784–792.
19. Bendorf A, Kelly PJ, Kendrige IH, et al. An international comparison of the effect of policy shifts to organ donation following cardiocirculatory death (DCD) on donation rates after brain death (DBD) and transplantation rates. PLoS One. 2013;8:e62010.
20. Sque M, Long T, Payne S. Organ donation: key factors influencing families’ decision-making. Transplant Proc. 2005;37:543–546.
21. Sela N, Croome KP, Chandok N, et al. Changing donor characteristics in liver transplantation over the last 10 years in Canada. Liver Transpl. 2013;19:1236–1244.
22. Orman ES, Mayorga ME, Wheeler SB, et al. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl. 2015;21:1040–1050.
23. Xu H, Berendt SN, Kim K, et al. Excorporeal normothermic machine perfusion resuscitates pig DCD livers with extended warm ischemia. J Surg Res. 2012;173:e83–e88.
24. Henry SD, Nachber E, Tulipan J, et al. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. Am J Transplant. 2012;12:2477–2486.
25. Jamieson RW, Zivot M, Roy D, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation. 2011;92:289–295.
26. Op den Dries S, Karimian N, Porte RJ. Normothermic machine perfusion of discarded liver grafts. Am J Transplant. 2013;13:2504.
27. Sutton M, Op den Dries S, Karimian N, et al. Criteria for viability assessment of discarded human donor livers during ex-vivo normothermic machine perfusion. Liver Transplantation. 2014;20:S240.
28. Mergenthal H, Perez M, Langer RW, et al. Transplantation of declined liver allografts following normothermic ex-situ evaluation. Am J Transplant. 2016.
29. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.